Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine

Article Abstract:

An international, randomized clinical trial was conducted to examine the effect BIBN 4096 BS on 126 patients with migraine after they received it intravenously over a period of ten minutes. The results showed that the Calcitonin gene-related peptide (CGRP) antagonist BIBN 4096 BS was effective in treating acute attacks of migraine.

Author: Hall, David, Olesen, Jes, Diener, Hans-Christoph, Husstedt, Ingo W., Goadsby, Peter J., Meier, Ulrich, Pollentier, Stephane
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
United States, Usage, Clinical trials, Peptides, Migraine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


NXY-059 for acute ischemic stroke

Article Abstract:

NXY-059, a free-radical-trapping agent that is neuroprotective in animal models of stroke is tested on humans to see if it would reduce disability after acute ischemic stroke. The results show a benefit in terms of the prespecified primary end point, a reduction in disability as measured by the modified Rankin score at 90 days.

Author: Diener, Hans-Christoph, Lees, Kennedy R., Davalos, Antonio, Grotta, James, Hardemark, Hans-Goran, Wasiewski, Warren W., Zivin, Justin A., Ashwood, Tim, Davis, Stephen M., Lyden, Patrick, Shuaib, Ashfaq
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
New England States, Health aspects, New England, Placebos

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


NXY-059 for the treatment of acute ischemic stroke

Article Abstract:

The efficacy of the free-radical-trapping agent NXY-059 as a neuroprotectant is assessed in the Stroke-Acute Ischemic NXY Treatment II (SAINT II) trial. The results have shown that NXY-059 is safe but ineffective for the treatment of acute ischemic stroke within 6 hours after the onset of symptoms.

Author: Diener, Hans-Christoph, Lees, Kennedy R., Davalos, Antonio, Grotta, James, Wasiewski, Warren W., Ashwood, Tim, Davis, Stephen M., Lyden, Patrick, Shuaib, Ashfaq, Emeribe, Ugochi
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
Diagnosis, Clinical report, Disease/Disorder overview

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Care and treatment, Research, Stroke (Disease), Stroke
Similar abstracts:
  • Abstracts: Somatostatin regulates brain amyloid beta peptide Abeta(sub 42) through modulation of proteolytic degradation
  • Abstracts: The effect of indomethacin and prostacyclin agonists on blood pressure in a rat model of preeclampsia. Comparing uterine electromyography activity of antepartum patients versus term labor patients
  • Abstracts: The effects of repeated spectroscopic pressure measurements on fluorescence intensity in the cervix. Laser scanning confocal microscopy of cervical tissue before and after application of acetic acid
  • Abstracts: Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization
  • Abstracts: Clinical supervision in a challenging behaviour unit. Understanding the value of qualitative research in nursing
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.